Trial Profile
An Open-Label, Expanded Access Program With Lenvatinib for the First Line Treatment of Unresectable Hepatocellular Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 07 Jan 2022
Price :
$35
*
At a glance
- Drugs Lenvatinib (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Expanded access
- Sponsors Eisai Co Ltd
- 09 Apr 2018 Status changed from recruiting to active, no longer recruiting.
- 08 Nov 2017 New trial record